
|Articles|November 26, 2012
FDA panel votes against OTC use of OAB agent
An FDA advisory panel voted against making oxybutynin transdermal patch (Oxytrol, Merck and Watson Pharma) available over-the-counter (OTC) for overactive bladder (OAB) in women, Medpage Today reported.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Drug Topics
1
New Study Finds Compounded GLP-1s Remain Robust Despite End of Shortages
2
ICER Report Finds GLP-1s Are Cost-Effective But Warns of Budget Strain
3
Postpartum Mothers Favor Bedtime Stopping Rule Over Stricter Chrononutrition Approaches
4
What’s Next for Pneumococcal Vaccination? An Expert Weighs In
5






























